Lantheus Holdings

NASDAQ LNTH
$54.75 0.93 1.73%
Today share price
USA
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 35 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
6.97B
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
6.60B
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.51
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
71.46M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-38.80 %

Upcoming events Lantheus Holdings

All events
No upcoming events scheduled

Stock chart Lantheus Holdings

Stock analysis Lantheus Holdings

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
27.42 -2.87
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
5.89 2.27
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
13.86 -0.89
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-0.78 0.32
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
21.85 -11.72

Price change Lantheus Holdings per year

51.87$ 116.69$
Min Max

Summary analysis Lantheus Holdings

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Lantheus Holdings

Revenue and net income Lantheus Holdings

All parameters

About company Lantheus Holdings

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Address:
331 Treble Cove Road, North Billerica, MA, United States, 01862
Company name: Lantheus Holdings
Issuer ticker: LNTH
ISIN: US5165441032
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2015-06-25
Sector: Healthcare
Site: https://www.lantheus.com